AUTHOR=Acquarone Mariana , de Melo Thiago M. , Meireles Fernanda , Brito-Moreira Jordano , Oliveira Gabriel , Ferreira Sergio T. , Castro Newton G. , Tovar-Moll Fernanda , Houzel Jean-Christophe , Rehen Stevens K. TITLE=Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of Parkinson’s disease JOURNAL=Frontiers in Cellular Neuroscience VOLUME=9 YEAR=2015 URL=https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2015.00097 DOI=10.3389/fncel.2015.00097 ISSN=1662-5102 ABSTRACT=

Parkinson’s disease (PD) is an incurable progressive neurodegenerative disorder. Clinical presentation of PD stems largely from the loss of dopaminergic neurons in the nigrostriatal dopaminergic pathway, motivating experimental strategies of replacement based on cell therapy. Transplantation of dopaminergic neurons derived from embryonic stem cells significantly improves motor functions in rodent and non-human primate models of PD. However, protocols to generate dopaminergic neurons from embryonic stem cells generally meet with low efficacy and high risk of teratoma formation upon transplantation. To address these issues, we have pre-treated undifferentiated mouse embryonic stem cells (mESCs) with the DNA alkylating agent mitomycin C (MMC) before transplantation. MMC treatment of cultures prevented tumorigenesis in a 12 week follow-up after mESCs were injected in nude mice. In 6-OH-dopamine-lesioned mice, intrastriatal injection of MMC-treated mESCs markedly improved motor function without tumor formation for as long as 15 months. Furthermore, we show that halting mitotic activity of undifferentiated mESCs induces a four-fold increase in dopamine release following in vitro differentiation. Our findings indicate that treating mESCs with MMC prior to intrastriatal transplant is an effective to strategy that could be further investigated as a novel alternative for treatment of PD.